查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2067647

北美靜脈輸液市場規模、佔有率和趨勢分析報告：按類型、營養成分和細分市場預測（2026-2033 年）

North America Intravenous Solutions Market Size, Share & Trends Analysis Report By Type (Total Parenteral Nutrition (TPN), Peripheral Parenteral Nutrition (PPN)), By Nutrients (Carbohydrates), And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

北美靜脈輸液市場概覽

預計到 2025 年，北美靜脈輸液市場價值將達到 56.1 億美元，預計到 2033 年將達到 111.8 億美元，2026 年至 2033 年的複合年成長率為 9.2%。

這是由於慢性病患病率上升、對腸外營養和重症監護支持的需求增加、先進的醫療保健基礎設施的存在以及北美各地手術數量眾多所致。

這些因素共同推動了醫院、加護病房和靜脈輸液中心對靜脈輸液的需求。隨著癌症、慢性腎臟病和胃腸道疾病等慢性疾病負擔的加重，需要長期靜脈輸液以進行補液、藥物輸送和營養支持的患者群體持續成長。美國疾病管制與預防中心 (CDC) 的一項 2025 年研究估計，屆時美國十分之六的成年人將至少患有一種慢性疾病，十分之四的成年人將患有兩種或兩種以上的慢性疾病。這表明對持續臨床管理的需求巨大。此外，美國癌症協會估計，到 2025 年，美國每年將新增超過 200 萬例癌症病例，其中許多患者需要靜脈輸液進行化療和支持治療，這將進一步增加對體液和電解質管理的需求。

此外，對腸外營養和重症監護支援的需求日益成長，顯著推動了市場發展，尤其是在加護病房(ICU)、新生兒護理和術後護理等領域。當無法進行口服或靜脈營養時，許多嚴重和營養不良的患者需要靜脈營養支持。這在嚴重、創傷、早產和複雜手術後的恢復期尤其明顯。全靜脈營養(TPN) 和周邊靜脈營養(PPN) 等治療方法已成為患者管理中不可或缺的一部分，從而推動了急診和重症監護環境中對靜脈輸液的需求。

此外，北美先進的醫療基礎設施和龐大的手術量顯著促進了市場成長。該地區擁有完善的醫院、門診手術中心和專科醫療機構網路，這些機構在許多醫療程序中常規應用靜脈輸液療法。從常規操作到複雜手術，持續靜脈輸液對於術前術後的穩定和復原至關重要。大量技術精湛的醫護人員和先進的治療技術的廣泛應用，確保了靜脈輸液在各種臨床環境中的持續高效使用。

此外，住院患者數量的增加和重症監護需求的成長也推動了靜脈輸液需求的擴大。醫療系統，特別是急診和急救系統面臨的日益沉重的負擔，進一步凸顯了穩定可靠的靜脈輸液供應的重要性。例如，2025年1月，百特國際公司將兩種氯化鈉靜脈輸液的配額提高至100%，以提高美國醫療系統的供應能力。然而，該公司報告稱，持續的供應鏈限制導致1-2週的延遲，部分醫院甚至面臨2-3週的延遲。這表明，不斷成長的臨床需求正迫使製造商提高產能並最佳化分銷網路，以防止供應中斷。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章 市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 商業環境分析

第4章：北美靜脈輸液市場：按類型、估計和趨勢分析

  • 按類型分類的市場佔有率和波動分析（2025 年和 2033 年）
  • 市場規模、預測與趨勢分析：按類型分類，2021-2033 年
  • 全靜脈營養（TPN）
  • 周邊靜脈營養（PPN）

第5章：北美靜脈輸液市場：基於營養成分的估算與趨勢分析

  • 按營養素分類的市佔率波動分析（2025 年和 2033 年）
  • 市場規模、預測與趨勢分析：按營養素分類，2021-2033 年
  • 碳水化合物
  • 單劑量氨基酸溶液
  • 維生素和礦物質（鹽和電解質）
  • 腸外脂肪乳劑
  • 其他

第6章：北美靜脈輸液市場：依最終用途分類的估算與趨勢分析

  • 按最終用途分類的市場佔有率和波動分析（2025 年和 2033 年）
  • 市場規模、預測和趨勢分析：按最終用途分類，2021-2033 年
  • 醫院
  • 靜脈輸液中心
  • 家庭醫療保健

第7章 北美靜脈輸液市場：各國估計與趨勢分析

  • 各國市場概覽
  • 各國市場：要點
  • 美國
    • 主要國家的趨勢
    • 法律規範
    • 競爭考察
  • 加拿大
    • 主要國家的趨勢
    • 法律規範
    • 競爭考察
  • 墨西哥
    • 主要國家的趨勢
    • 法律規範
    • 競爭考察

第8章 競爭情勢

  • 參與企業概況
  • 2025年公司市場分析
  • 企業市場占有率分析，2025 年（%）
  • 公司分類
  • 策略規劃
  • 公司簡介列表
    • Baxter
    • Fresenius Kabi AG
    • B. Braun AG
    • ICU Medical, Inc.
    • Pfizer Inc.
    • Otsuka Pharmaceutical Co., Ltd.
    • Grifols, SA
    • JW Life Science
    • CSLVifor（前身為Vifor Pharma）
    • BD（Becton, Dickinson and Company）
    • Terumo Corporation
    • Amphastar Pharmaceuticals, Inc.
Product Code: GVR-4-68040-910-4

North America Intravenous Solutions Market Summary

The North America intravenous solutions market size was estimated at USD 5.61 billion in 2025 and is projected to reach USD 11.18 billion by 2033, growing at a CAGR of 9.2% from 2026 to 2033. The rising prevalence of chronic diseases, the increasing demand for parenteral nutrition and critical care support, and the presence of advanced healthcare infrastructure, coupled with high surgical volumes across North America.

These factors collectively drive the demand for intravenous solutions across hospitals, intensive care units, and infusion centers. The rising burden of chronic diseases including cancer, chronic kidney disease, and gastrointestinal disorders continues to expand the patient pool requiring long-term intravenous therapy for hydration, drug delivery, and nutritional support. According to the Centers for Disease Control and Prevention published study in 2025, 6 in 10 adults in the U.S. have at least one chronic disease, and 4 in 10 have two or more. This highlights a significant demand for ongoing clinical management. In addition, the American Cancer Society estimates over 2 million new cancer cases annually in the U.S. in 2025, many requiring IV solutions for chemotherapy and supportive care, which drives the need for IV fluid and electrolyte management.

Moreover, the increasing demand for parenteral nutrition and critical care support significantly drives the market, especially in intensive care units (ICUs), neonatal care, and post-surgical settings. A growing number of critically ill and malnourished patients require intravenous nutritional support when oral or enteral feeding is not possible. This is particularly true in cases of severe illness, trauma, premature births, and complex surgical recoveries. Therapies such as total parenteral nutrition (TPN) and peripheral parenteral nutrition (PPN) have become essential in patient management, boosting the demand for IV solutions in acute and critical care environments.

In addition, advanced healthcare infrastructure and high surgical volumes in North America contribute significantly to market growth. The region has a well-established network of hospitals, ambulatory surgical centers, and specialized care facilities that routinely use intravenous therapies for many medical procedures. Surgical interventions, from routine to complex, require consistent administration of IV fluids for perioperative stabilization and post-operative recovery. The strong presence of skilled healthcare professionals and broad access to advanced treatment technologies ensure the continued efficient use of IV solutions across clinical settings.

Furthermore, the increasing demand for intravenous fluids is further driven by rising hospital admissions and critical care needs. The growing burden on healthcare systems, especially in acute and emergency care, has intensified the need for a consistent, reliable supply of IV solutions. For instance, in January 2025, Baxter International Inc. increased allocations of two sodium chloride IV solutions to 100% to improve product availability across the U.S. healthcare system. However, the company reported a 1-2-week distribution lag, with some hospitals experiencing delays of 2-3 weeks due to ongoing supply chain constraints. This shows how rising clinical demand is pushing manufacturers to enhance production capacity and streamline distribution networks to ensure uninterrupted supply.

North America Intravenous Solutions Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the North America intravenous solutions market report based on type, nutrients, end use and regions:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Total Parenteral Nutrition Market (TPN)
  • Peripheral Parenteral Nutrition (PPN)
  • Nutrients Outlook (Revenue, USD Million, 2021 - 2033)
  • Carbohydrates
  • Single dose amino acid solution
  • Vitamins & Minerals (Salt and electrolyte)
  • Parenteral lipid emulsion
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Infusion Centers
  • Home Healthcare
  • Country Outlook (Revenue, USD Million, 2021 - 2033)
  • U.S.
  • Canada
  • Mexico

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Nutrients
    • 1.2.3. End use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
    • 1.8.2. Volume Price Analysis
    • 1.8.3. Triangulation Analysis
    • 1.8.4. CAGR Growth Assumption and Logics
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing Demand for Parenteral Nutrition and Critical Care Support
      • 3.2.1.2. Advanced Healthcare Infrastructure & High Surgical Volume
      • 3.2.1.3. Rising Prevalence of Chronic Diseases
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Stringent Regulatory Requirements
      • 3.2.2.2. Supply Chain Disruptions & High Production Costs
    • 3.2.3. Industry Opportunity Analysis
    • 3.2.4. Industry Challenge Analysis
    • 3.2.5. Pricing Analysis
    • 3.2.6. Emerging Trends
  • 3.3. Business Environment Analysis
    • 3.3.1. Porter's Five Forces Analysis
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTLE Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic and Social landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Environmental landscape
      • 3.3.2.5. Legal Landscape

Chapter 4. North America Intravenous Solutions Market: Type Estimates & Trend Analysis

  • 4.1. Type Segment Dashboard
  • 4.2. Type Market Share Movement Analysis, 2025 & 2033
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 4.4. Total Parenteral Nutrition Market (TPN)
    • 4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Peripheral Parenteral Nutrition (PPN)
    • 4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. North America Intravenous Solutions Market: Nutrients Estimates & Trend Analysis

  • 5.1. Nutrients Segment Dashboard
  • 5.2. Nutrients Market Share Movement Analysis, 2025 & 2033
  • 5.3. Market Size & Forecasts and Trend Analysis, by Nutrients, 2021 to 2033 (USD Million)
  • 5.4. Carbohydrates
    • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Single dose amino acid solution
    • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Vitamins & Minerals (Salt and electrolyte)
    • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Parenteral lipid emulsion
    • 5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.8. Others
    • 5.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. North America Intravenous Solutions Market: End Use Estimates & Trend Analysis

  • 6.1. End use Segment Dashboard
  • 6.2. End use Market Share Movement Analysis, 2025 & 2033
  • 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 6.4. Hospitals
    • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Infusion Centers
    • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Home Healthcare
    • 6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. North America Intravenous Solutions Market: Country Estimates & Trend Analysis

  • 7.1. Country Market Dashboard
  • 7.2. Country Market: Key Takeaways
  • 7.3. U.S.
    • 7.3.1. Key country dynamic
    • 7.3.2. Regulatory framework
    • 7.3.3. Competitive insights
    • 7.3.4. U.S. Intravenous Solutions market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4. Canada
    • 7.4.1. Key country dynamic
    • 7.4.2. Regulatory framework
    • 7.4.3. Competitive insights
    • 7.4.4. Canada Intravenous Solutions market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5. Mexico
    • 7.5.1. Key country dynamic
    • 7.5.2. Regulatory framework
    • 7.5.3. Competitive insights
    • 7.5.4. Mexico Intravenous Solutions market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis, 2025
  • 8.3. Company Market Share Analysis, 2025 (%)
  • 8.4. Company Categorization
  • 8.5. Strategy Mapping
  • 8.6. Company Profiles/Listing
    • 8.6.1. Baxter
      • 8.6.1.1. Overview
      • 8.6.1.2. Financial performance
      • 8.6.1.3. Product benchmarking
      • 8.6.1.4. Strategic initiatives
    • 8.6.2. Fresenius Kabi AG
      • 8.6.2.1. Overview
      • 8.6.2.2. Financial performance
      • 8.6.2.3. Product benchmarking
      • 8.6.2.4. Strategic initiatives
    • 8.6.3. B. Braun AG
      • 8.6.3.1. Overview
      • 8.6.3.2. Financial performance
      • 8.6.3.3. Product benchmarking
      • 8.6.3.4. Strategic initiatives
    • 8.6.4. ICU Medical, Inc.
      • 8.6.4.1. Overview
      • 8.6.4.2. Financial performance
      • 8.6.4.3. Product benchmarking
      • 8.6.4.4. Strategic initiatives
    • 8.6.5. Pfizer Inc.
      • 8.6.5.1. Overview
      • 8.6.5.2. Financial performance
      • 8.6.5.3. Product benchmarking
      • 8.6.5.4. Strategic initiatives
    • 8.6.6. Otsuka Pharmaceutical Co., Ltd.
      • 8.6.6.1. Overview
      • 8.6.6.2. Financial performance
      • 8.6.6.3. Product benchmarking
      • 8.6.6.4. Strategic initiatives
    • 8.6.7. Grifols, S.A.
      • 8.6.7.1. Overview
      • 8.6.7.2. Financial performance
      • 8.6.7.3. Product benchmarking
      • 8.6.7.4. Strategic initiatives
    • 8.6.8. JW Life Science
      • 8.6.8.1. Overview
      • 8.6.8.2. Financial performance
      • 8.6.8.3. Product benchmarking
      • 8.6.8.4. Strategic initiatives
    • 8.6.9. CSLVifor (formerly Vifor Pharma)
      • 8.6.9.1. Overview
      • 8.6.9.2. Financial performance
      • 8.6.9.3. Product benchmarking
      • 8.6.9.4. Strategic initiatives
    • 8.6.10. BD (Becton, Dickinson and Company)
      • 8.6.10.1. Overview
      • 8.6.10.2. Financial performance
      • 8.6.10.3. Product benchmarking
      • 8.6.10.4. Strategic initiatives
    • 8.6.11. Terumo Corporation
      • 8.6.11.1. Overview
      • 8.6.11.2. Financial performance
      • 8.6.11.3. Product benchmarking
      • 8.6.11.4. Strategic initiatives
    • 8.6.12. Amphastar Pharmaceuticals, Inc.
      • 8.6.12.1. Overview
      • 8.6.12.2. Financial performance
      • 8.6.12.3. Product benchmarking
      • 8.6.12.4. Strategic initiatives

List of Tables

  • Table 1. List of abbreviations
  • Table 2. List of secondary data sources
  • Table 3. North America Intravenous Solutions market, by country, 2021 - 2033 (USD Million)
  • Table 4. North America Intravenous Solutions market, by type, 2021 - 2033 (USD Million)
  • Table 5. North America Intravenous Solutions market, by nutrients, 2021 - 2033 (USD Million)
  • Table 6. North America Intravenous Solutions market, by end use, 2021 - 2033 (USD Million)
  • Table 7. U.S. Intravenous Solutions market, by type, 2021 - 2033 (USD Million)
  • Table 8. U.S. Intravenous Solutions market, by nutrients, 2021 - 2033 (USD Million)
  • Table 9. U.S. Intravenous Solutions market, by end use, 2021 - 2033 (USD Million)
  • Table 10. Canada Intravenous Solutions market, by type, 2021 - 2033 (USD Million)
  • Table 11. Canada Intravenous Solutions market, by nutrients, 2021 - 2033 (USD Million)
  • Table 12. Canada Intravenous Solutions market, by end use, 2021 - 2033 (USD Million)
  • Table 13. Mexico Intravenous Solutions market, by type, 2021 - 2033 (USD Million)
  • Table 14. Mexico Intravenous Solutions market, by nutrients, 2021 - 2033 (USD Million)
  • Table 15. Mexico Intravenous Solutions market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Market formulation & validation
  • Fig. 4 North America Intravenous Solutions market: Market outlook
  • Fig. 5 North America Intravenous Solutions market: Segment outlook
  • Fig. 6 North America Intravenous Solutions market: Competitive landscape outlook
  • Fig. 7 Parent market outlook
  • Fig. 8 North America Intravenous Solutions Market Driver Impact
  • Fig. 9 North America Intravenous Solutions market Restraint impact
  • Fig. 10 North America Intravenous Solutions market, Type outlook key takeaways (USD Million)
  • Fig. 11 North America Intravenous Solutions market: Type movement analysis (USD Million)
  • Fig. 12 Total Parenteral Nutrition Market (TPN) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 13 Peripheral Parenteral Nutrition (PPN) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 14 North America Intravenous Solutions market, Nutrients outlook: Key takeaways, (USD Million)
  • Fig. 15 North America Intravenous Solutions market: Nutrients movement analysis, (USD Million)
  • Fig. 16 Carbohydrates market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 17 Single dose amino acid solution market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 18 Vitamins & Minerals (Salt and electrolyte) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 19 Parenteral lipid emulsion market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 20 North America Intravenous Solutions market, end use outlook key takeaways (USD Million)
  • Fig. 21 North America Intravenous Solutions market: end use movement analysis, (USD Million)
  • Fig. 22 Hospitals market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Infusion Centers market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Home Healthcare market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Country marketplace: Key takeaways
  • Fig. 26 North America Intravenous Solutions market: Country outlook, 2025 & 2033
  • Fig. 27 US Intravenous Solutions market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Canada Intravenous Solutions market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Mexico Intravenous Solutions market estimates and forecasts, 2021 - 2033 (USD Million)